Research article

Biotransformation of major ginsenosides in ginsenoside model culture by lactic acid bacteria

Seong-Eun Park *, Chang-Su Na *, Seon-A Yoo, Seung-Ho Seo, Hong-Seok Son *

School of Oriental Medicine, Dongshin University, Naju, Jeonnam, Korea

Article info

Article history:
Received 5 November 2015
Received in Revised form 16 December 2015
Accepted 18 December 2015
Available online 28 December 2015

Keywords:
biotransformation
fermentation
ginseng
ginsenoside
lactic acid bacteria

Abstract

Background: Some differences have been reported in the biotransformation of ginsenosides, probably due to the types of materials used such as ginseng, enzymes, and microorganisms. Moreover, most microorganisms used for transforming ginsenosides do not meet food-grade standards. We investigated the statistical conversion rate of major ginsenosides in ginsenosides model culture during fermentation by lactic acid bacteria (LAB) to estimate possible pathways.

Methods: Ginsenosides standard mix was used as a model culture to facilitate clear identification of the metabolic changes. Changes in eight ginsenosides (Rb1, Rb2, Rc, Rd, Re, Rf, Rg1, and Rg2) during fermentation with six strains of LAB were investigated.

Results: In most cases, the residual ginsenoside level decreased by 5.9–36.8% compared with the initial ginsenoside level. Ginsenosides Rb1, Rb2, Rc, and Re continuously decreased during fermentation. By contrast, Rd was maintained or slightly increased after 1 d of fermentation. Rg1 and Rg2 reached their lowest values after 1–2 d of fermentation, and then began to increase gradually. The conversion of Rd, Rg1, and Rg2 into smaller deglycosylated forms was more rapid than that of Rd from Rb1, Rb2, and Rc, as well as that of Rg1 and Rg2 from Re during the first 2 d of fermentation with LAB.

Conclusion: Ginsenosides Rb1, Rb2, Rc, and Re continuously decreased, whereas ginsenosides Rd, Rg1, and Rg2 increased after 1–2 d of fermentation. This study may provide new insights into the metabolism of ginsenosides and can clarify the metabolic changes in ginsenosides biotransformed by LAB.

1. Introduction

Ginseng (Panax ginseng Meyer) is a traditional herbal medicine that has been used for a long time in Asia because of its numerous medicinal functions [1] and its use continues to increase worldwide. Ginseng contains various bioactive components, including ginsenosides (ginseng saponins), acidic polysaccharides, polyphenols, and polyacetylenes [2]. Among these components, ginsenosides, which are glycosides with steroids or triterpenes as aglycons, have been highly characterized for their biological activities. To date, more than 50 ginsenosides have been identified and are divided into two major categories based on their chemical structures: (1) propanaxadiol [PPD, aglycone (20S)-protopanaxadiol], which includes ginsenosides Rb1, Rb2, Rc, Rd, Rg3, compound K (CK), and Rh2, and (2) protopanaxatriol [PPT, aglycone (20S)-protopanaxatriol], which includes ginsenosides Re, Rf, Rg1, Rg2, and Rh1 [3]. Among those, six major ginsenosides (Rb1, Rb2, Rc, Rd, Re, and Rg1) have been determined to account for 90% of the total ginsenoside content of P. ginseng Meyer [4].

The sugar chains of ginsenosides were found to be closely related to their functionality. The conversion of ginsenosides into smaller deglycosylated forms may therefore markedly change the biological activity especially effective for in vivo physiological actions [5]. For example, CK transformed from ginsenosides Rb1, Rb2, and Rc was reported to demonstrate improved anti-inflammatory and antitumor effects [6,7]. Therefore, the transformation of these major ginsenosides (Rb1, Rb2, Rc, Rd, Re, and Rg1) into smaller deglycosylated ginsenosides is necessary. Many studies have
focused on the conversion of major ginsenosides into more active deglycosylated forms using physicochemical transformation methods such as heating and acid treatment [8,9]. By contrast, biological approaches such as microbial or enzymatic methods have been proposed, owing to their marked selectivity, mild reaction conditions, environmental compatibility, and convenience for industrial applications [10,11]. Many studies have identified the biotransformation of ginsenosides into smaller deglycosylated forms such as Rb1 → Rd, Rf, Rg3, CK [12], Re, Rb1, Rc → Rg1, Rd, CK [13], RB1 → RD [11], and RB1 → RD, Rg3 [10]. The structures and possible biotransformation pathways of PPD- and PPT-type ginsenosides by microbial or enzymatic methods are shown in Fig. 1. The specific pathways of the PPD and PPT ginsenosides were indicated based on published information (see Table S1 in Supplementary Material online). Some differences in the biotransformation of ginsenosides have been reported according to the biological methods used; however, these differences may also be due to the types of materials used such as ginseng, enzymes, and microorganisms. Moreover, most microorganisms used for biological transformation do not satisfy food-grade standards [14].

Characterization of the biotransformation of ginsenosides during fermentation is needed to explain the pharmacological actions of fermented ginseng. However, most reports only deal with one or a few ginsenosides, ignoring the full action of ginsenosides. Moreover, the ginsenosides levels in ginseng plants are influenced by a range of factors such as the species, age, part of the plant, cultivation method, harvesting season, and preservation method [15]. It can be difficult to clearly identify the comprehensive ginsenoside transformation, probably due to the chemical complexity of the metabolites, the lack of reference standards, experimental error during the extraction of ginsenosides, or the limitations inherent in analytical methods [16]. Therefore, the investigation of targeted changes in major ginsenosides during fermentation with selected microorganisms is needed [17].

In this paper, the biotransformation in ginsenosides using food-compatible microorganisms [lactic acid bacteria (LAB)] was identified and quantified. A standard mix of ginsenosides containing eight major ginsenosides was used as a model culture to facilitate clear identification of the metabolic changes.

2. Materials and methods

2.1. Materials

Ginseng ginsenosides mix, including Rb1, Rb2, Rc, Rd, Re, Rf, Rg1, and Rg2 (100 μg/mL of each component in methanol), was purchased from Sigma-Aldrich (St. Louis, MO, USA). Methanol (1 mL) was evaporated under vacuum using liquid nitrogen, and diluted with 100 mL of distilled water for use as a ginsenosides model culture (GMC) for LAB.

2.2. Fermentation

Six LAB strains were selected for this study based on β-glucosidase activity as previously reported [18,19]. Lactobacillus plantarum KCCM11322, Lactobacillus delbrueckii subsp. bulgaricus KCCM35463, Lactobacillus fermentum KCCM40401, and Bifidobacterium longum KCCM11953 were purchased from the Korean Culture Center of Microorganisms (KCCM, Seoul, Korea). L. delbrueckii subsp. lactis KCTC 1058 and Leuconostoc mesenteroides subsp. mesenteroides KCTC 3718 were purchased from the Korean Collection for Type Cultures (KCTC, Daejeon, Korea). The strain was inoculated into Man–Rogosa–Sharpe (MRS, Difco, Sparks, MD, USA) broth and grown at 37 °C for 48 h to obtain a final cell count of 10^8 CFU/mL. GMC was produced using ginseng ginsenosides mix diluted with distilled water by supplementing MRS broth (5.5%) with the LAB nutrient. GMC was inoculated with 1% (vol/vol) of LAB starter culture and fermentation was performed at 30 °C for 5 d. Samples were taken on the 1st, 2nd, 3rd, and 5th days of fermentation for chemical and microbiological analyses.

2.3. Microbiological analysis

One milliliter of GMC was aseptically transferred into a conical tube prior to the preparation of 1/10 serial dilutions for microbiological analysis. LAB count was determined after growing the LAB in MRS agar and incubating at 37 °C for 48 h. Tests were carried out in duplicate and the results were expressed as log CFU/g.

2.4. Physicochemical analysis

After centrifuging for 5 min at 12,000 rpm, the supernatant liquid was filtered through a 0.45-μm membrane (Whatman No. 2) and used in all of the test systems. The total soluble solids (degrees Brix) in GMC were measured using a digital refractometer (PR-32, Atago, Tokyo, Japan) with temperature compensation. pH was determined using a pH meter (pH-250L, ISTEK, Seoul, Korea) and the means of three measurements were recorded. Titratable acidity (TA) as lactic acid was determined by titrating to pH 8.3 with 0.1N NaOH. Reducing sugars were measured according to the 3,5-dinitrosalicylic acid (DNS) method [20]. Reaction mixtures contained 3 mL of the sample and 3 mL of the DNS reagent. Glucose solution was used for the standard curve. The reaction mixture was heated in a water bath for 5 min to develop a red-brown color and was then cooled to room temperature in a water-ice bath. Subsequently, 1 mL of a 40% potassium sodium tartrate solution was added to stabilize the color. The absorbance was measured at 540 nm using a spectrophotometer (UV-1601; Shimadzu, Kyoto, Japan).

2.5. β-glucosidase activity

Beta-glucosidase activity was evaluated via the colorimetric method using p-nitrophenyl-β-D-glucopyranoside (pNPG) as a substrate [10]. The reaction mixture, which contained 5mM of pNP in 1 mL of sodium phosphate buffer (pH 7.0) and 100 μL of enzyme solution, was incubated at 30 °C for 10 min. The reaction was subsequently terminated by adding 1 mL of 0.5M NaOH, and the absorption of the released p-nitrophenol (PNP) was measured against the prepared reagent blank at 400 nm using a spectrophotometer. One unit of β-glucosidase activity was defined as the quantity of enzyme required to liberate 1 μM of pNP/min under standard conditions.

2.6. Ginsenosides analysis

Eight ginsenoside peaks were detected by liquid chromatography (Agilent 1200 Series) coupled with 6410A triple quadrupole mass spectrometry (Agilent, Santa Clara, California, USA). Samples were ionized and detected by electrospray ionization—mass spectrometry with the selected ion-monitoring mode of negative ions. The nebulizer gas was set to 10 L/min at a temperature of 320 °C and the capillary voltages were set to 4 kV. Separation was achieved using the XDB-C18 column (50 mm × 4.6 mm i.d., 1.8 μm; Agilent) with a column oven temperature of 35 °C. The mobile phase was composed of (A) 5mM ammonium acetate–formic acid (0.1%, vol/vol) and (B) methanol. The mobile phase B was kept at 50% for 2 min and then gradually increased to 90% for 25 min. The flow rate was kept at 0.35 mL/min, and 5 μL of the sample solution was injected in each run.
Fig. 1. The structures and possible biotransformation pathways of (A) protopanaxadiol (PPD)- and (B) protopanaxatriol (PPT)-type ginsenosides by microbial or enzymatic methods. The pathways of ginsenosides were drawn based on published information and the reference numbers are indicated in Table S1 (see Supplementary Material online). The fundamental chemical structures of ginsenosides were simply expressed to highlight their conversion into smaller deglycosylated forms.
2.7. Statistical analysis

Statistical analyses were performed using the SPSS version 14.0 statistical package for windows (SPSS Inc., Chicago, IL, USA). Analysis of variance and Duncan multiple range tests were applied to the data to determine significant differences, and a value of \( p < 0.05 \) was considered statistically significant.

3. Results and discussion

3.1. Microbiological analysis

The structures and possible biotransformation pathways of PPD- and PPT-type ginsenosides by microbial or enzymatic methods are shown in Fig. 1. The specific pathways of the PPD and PPT ginsenosides were indicated based on published information (see Table S1 in Supplementary Material online). Some differences have been reported in the biotransformation of ginsenosides according to the types of materials used such as ginseng, enzymes, and microorganisms. We investigated the statistical conversion rate of major ginsenosides (Rb1, Rb2, Rc, Rd, Re, Rg1, and Rg2) in GMC during fermentation by LAB to estimate the possible pathways involved.

Fig. 2 shows the growth kinetics of LAB during fermentation in GMCs inoculated with six strains of LAB. Each batch was inoculated with 1% LAB by volume, with a final cell count of 8–9 log CFU/mL. GMCs contained about 9–11 log CFU/mL on the 1st day of fermentation, which increased slightly on the 2nd day of fermentation, with the exception of one starter culture (\( L. \) fermentum). Afterward, the number of viable cells in GMCs began to decrease and the cell population reached 6–7.5 log CFU/mL in all tested samples after 5 d of fermentation. Although similar, the population growth pattern displayed by LAB in GMCs showed several variations in the inoculated strains.

3.2. Physicochemical analysis

The reducing sugar contents before fermentation of the GMCs was 550 mg/L. The reducing sugars were depleted to 20–25 mg/L by all strains except for \( L. \) delbrueckii subsp. bulgaricus (68 mg/L, data not shown). These results confirmed that fermentable sugar was almost exhausted within the 5 d of fermentation. The pH and the TA of GMCs fermented with the six LAB strains are presented in Fig. 3. The pH of GMCs before inoculation was 6.37 and the value decreased during fermentation. Although the viable LAB numbers in the GMCs inoculated with \( L. \) fermentum and \( B. \) longum were relatively higher than those in other samples during fermentation, the pH values were significantly higher at 4.2–4.3 compared with the other GMCs (3.8–3.9). In general, the TA was inversely proportional to the pH value. As expected, the GMCs inoculated with \( L. \) fermentum and \( B. \) longum had lower TA values, with final values of 0.92–1.02%. GMCs inoculated with other strains had significantly higher TA value of 1.37–1.53%. It may be that the pH reduction was due to LAB rapidly becoming the predominant microorganism, producing lactic acid and leading to pH reduction.

3.3. \( \beta \)-glucosidase activity

The \( \beta \)-glucosidase activity of GMCs fermented with six LAB strains are listed in Fig. 4. As the fermentation progressed, \( \beta \)-glucosidase activity of all GMCs increased and peaked at 2 d of fermentation. However, after 2 d of fermentation, the \( \beta \)-glucosidase activity in the samples began to decrease and reached 74–109 U in all tested samples on the 5th day of fermentation. Although \( \beta \)-glucosidase activity was lower compared with the 2nd day of fermentation, its activity in the GMCs inoculated with \( L. \) mesenteroides and \( L. \) plantarum stabilized or decreased slowly by the 5th day of fermentation. This indicated that a fermentation period longer than 5 d was needed for the biotransformation of ginsenosides. By contrast, large and rapid decrease in \( \beta \)-glucosidase activity was observed in the GMCs inoculated with \( L. \) fermentum and \( B. \) longum. The \( \beta \)-glucosidase activity pattern displayed by \( L. \) delbrueckii subsp. bulgaricus in GMC was significantly lower than other tested samples during fermentation. Because of the special structure of the dammarane skeleton,
only specific β-glucosidases hydrolyze ginsenoside-β-glucoside linkages [14]. To date, several β-glucosidases producing LABs have been reported [21–23]. Yan et al [24] purified seven β-glucosidase fractions from Paecilomyces Bainier sp. 229, and found that the biotransformation pathway of Rb1 to CK by each fraction was different. Specific bioconversion of ginsenoside Rb1 into various ginsenosides may be possible using the appropriate combination of specific microbial enzymes.

3.4. Biotransformation of ginsenosides

The residual ginsenoside levels on the 5th day of fermentation are shown in Table 1. In most cases, the residual ginsenoside level decreased by 5.9–36.8% compared with the initial value. Among PPD-type ginsenosides, ginsenoside Rd was at the highest level after 5 d of fermentation. Rd is the major ginsenoside in the final fermentation product [13], and it can be converted from Rb1, Rb2, and Rc by the removal of sugar (Fig. 1). We, therefore, suggest that the relatively higher level of Rd was due to the conversion of Rb1, Rb2, and Rc during fermentation. The time courses of ginsenosides concentrations during fermentation are shown in Fig. 5. These results confirmed that Rb1, Rb2, and Rc decreased continuously during the 5 d of fermentation. By contrast, Rd was maintained or slightly increased after 1 d of fermentation. In particular, a dramatic increase in Rd was observed in the GMC inoculated with L. delbrueckii subsp. bulgaricus, which had relatively low β-glucosidase activity during fermentation. Many studies have been conducted on the biotransformation of the ginsenoside Rb1 into Rd during fermentation [110,24]. However, Rd can be continuously converted into CK by cell extracts from various food-grade edible microorganisms including L. mesenteroides [25] and Lactobacillus paralimentarius [26]. We confirmed that Rd decreased during the first 2 d of fermentation, suggesting that it can be converted more quickly into smaller deglycosylated forms such as Rg3, Rh2, F1, and CK [27,28]. Ye et al [1] reported that Rd yields from Rb1 were low due to the inhibition of Rd production by other ginsenosides, low substrate tolerance, requirement for pure substrates, and further transformation of Rd into other compounds. In this paper, we used the same concentration of ginsenosides standard (1 ppm) as a culture to investigate the reaction rates related to the conversion of ginsenosides into their smaller deglycosylated forms. In our model culture, it appeared that the conversion rate of Rd into its smaller deglycosylated form was more rapid than that of Rd from Rb1, Rb2, and Rc.

Among PPT-type ginsenosides, a low level of Re was observed in the GMCs after fermentation (Table 1). The decrease in Re concentration during fermentation is in agreement with other studies, but to varying degrees according to the LAB strain. The evolution of Rg1 and Rg2 contents in the GMC inoculated with LAB was very different from the other ginsenosides (Fig. 5). Unlike other ginsenosides, Rg1 and Rg2 reached their lowest levels after 1–2 d of fermentation and then increased gradually. In all cases, Rg1 and Rg2 levels in GMCs fermented with LAB were significantly higher than in other samples after fermentation, indicating that Rg1 and Rg2 were intermediate products of Re and that the bioconversion rate of Re into deglycosylated forms such as F1 and Rh1 was slower than those of other ginsenosides. Many studies have reported a decrease in Re and an increase in Rh2 during fermentation. However, the opposite was reported for Rg1 change during fermentation. Hsu et al [13] showed that after 30 d of fermentation with Ganoderma lucidum, ginsenoside Rg1 increased significantly, whereas ginsenoside Re decreased during fermentation. Wang et al [16] reported that Re and Rg1 were decreased slightly, whereas Rg2 and Rh1 were increased in red ginseng extract fermented by human intestinal microflora. The contrast in Rg1 changes during fermentation seems to be due to differences in bioconversion conditions such as microorganism and microbial enzymes. To avoid variability in the preparations, this research used commercially available ginsenoside mix as a model culture, and the time courses of ginsenoside concentrations during fermentation with LAB were studied. In our model system, the conversion rate of Rg1 and Rg2 during fermentation may have been similar because we added the same concentration of ginsenosides standard (1 ppm) before fermentation. Moreover, we confirmed that the conversion rate of Rg1 and Rg2 into smaller deglycosylated forms such as F1 and Rh1 was faster than the conversion rate from Re during the first 2 d of fermentation by LAB.

Although ginsenoside Rf is known to have higher chemical stability than other ginsenosides, it was reported that Rf transformed into ginsenoside Rg9 through a dehydration reaction under thermal and acidic conditions [29]. However, this transformation is not due to the removal of sugar from Rf leading to transformation into a smaller deglycosylated form. Rf does not have the readily hydrolytic sugar bonded to the hydroxyl at 21-C in its dammarane skeleton [30]. In this study, it may be that Rf was converted into other forms by LAB, but high variability was found among the samples.

The time courses of ginsenosides concentrations during fermentation with LAB were studied and commercially available ginsenoside mix was used as a model culture for the clear identification of the metabolic changes in ginsenosides. Among PPD-type ginsenosides, although ginsenosides Rb1, Rb2, and Rc decreased

| Ginsenosides | Lactobacillus fermentum | Lactobacillus delbrueckii subsp. lactis | Bifidobacterium longum | Leuconostoc mesenteroides | Lactobacillus plantarum | L. delbrueckii subsp. bulgaricus | Average |
|--------------|------------------------|--------------------------------------|-----------------------|-------------------------|-------------------------|---------------------------------|---------|
| PPD Rb1      | 0.772 ± 0.025^A1B1     | 0.624 ± 0.010^A1B2                  | 0.579 ± 0.089^A1B3    | 0.797 ± 0.005^A1B4     | 0.597 ± 0.041^A1B5     | 0.736 ± 0.017^A1B6             | 0.685   |
| PPD Rb2      | 0.682 ± 0.064^A1B1B2   | 0.569 ± 0.014^A1B3                  | 0.607 ± 0.007^A1B4    | 0.708 ± 0.069^A1B5     | 0.506 ± 0.012^A1B6     | 0.719 ± 0.099^A1B7             | 0.632   |
| PPD Rc       | 0.676 ± 0.072^A1B1B2   | 0.597 ± 0.012^A1B3                  | 0.630 ± 0.007^A1B4    | 0.683 ± 0.063^A1B5     | 0.569 ± 0.061^A1B6     | 0.703 ± 0.069^A1B7             | 0.643   |
| PPD Rg1      | 0.589 ± 0.103^A1B1B2   | 0.741 ± 0.093^A1B3                  | 0.620 ± 0.114^A1B4    | 0.817 ± 0.075^A1B5     | 0.672 ± 0.053^A1B6     | 1.022 ± 0.069^A1B7             | 0.777   |
| PPD Rg2      | 0.728 ± 0.023^A1B1B2   | 0.723 ± 0.150^A1B3                  | 0.632 ± 0.067^A1B4    | 0.884 ± 0.112^A1B5     | 0.661 ± 0.053^A1B6     | 0.804 ± 0.017^A1B7             | 0.739   |
| PPD Rg3      | 0.912 ± 0.070^A1B1B2   | 0.863 ± 0.003^A1B3                  | 0.905 ± 0.008^A1B4    | 0.959 ± 0.002^A1B5     | 0.841 ± 0.027^A1B6     | 0.954 ± 0.021^A1B7             | 0.906   |
| PPD Rg2      | 0.905 ± 0.065^A1B1B2   | 0.905 ± 0.007^A1B3                  | 0.971 ± 0.007^A1B4    | 0.947 ± 0.013^A1B5     | 0.917 ± 0.026^A1B6     | 0.999 ± 0.003^A1B7             | 0.941   |
| PPD Rf       | 0.423 ± 0.008^A1B1B2   | 1.150 ± 0.214^A1B3                  | 0.783 ± 0.239^A1B4    | 0.724 ± 0.018^A1B5     | 0.386 ± 0.097^A1B6     | 0.693 ± 0.260^A1B7             | 0.693   |
| Total        | 5.691 ± 0.029          | 6.176 ± 0.464                       | 5.912 ± 0.573         | 6.522 ± 0.991         | 5.152 ± 0.103         | 6.634 ± 0.075                   |         |

Values with different small letters in a column and capital letters in a row are significantly different at p < 0.05
PPD: protopanaxadiol; PPT: protopanaxatriol
1) Mean ± SD (n = 3)
continuously, Rd was maintained or increased slightly after 1 d of fermentation, suggesting that the conversion rate of Rd into smaller deglycosylated forms was more rapid than that of Rb1, Rb2, and Rc. Among PPT-type ginsenosides, Re decreased continuously, whereas ginsenosides Rg1 and Rg2 increased after 1–2 d of fermentation, indicating that these ginsenosides were the intermediate products of Re, and that the bioconversion of Re into smaller deglycosylated forms was faster than the conversion rate from Re during the first 2 d of fermentation by LAB.

Conflicts of interest

The authors have no conflicts of interest with any parties or individuals.

Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.jgr.2015.12.008.

References

[1] Ye L, Zhou CQ, Zhou W, Zhou P, Chen DF, Liu XH, Shi XL, Feng MQ. Biotransformation of ginsenoside Rb1 to ginsenoside Rd by highly substrate-tolerant Paecilomyces Bainier 229-7. Bioresour Technol 2010;101:7872–6.
[2] Baque MA, Moh SH, Lee EJ, Zhong JJ, Paek KY. Production of biomass and useful compounds from adventitious roots of high-value added medicinal plants using bioreactor. Biotechnol Adv 2012;30:1255–67.
[3] Jia L, Zhao Y, Liang XJ. Current evaluation of the millennium phytomedicine—ginseng (II): collected chemical entities, modern pharmacology, and
clinical applications eminated from traditional Chinese medicine. Curr Med Chem 2009;16:2924–42.
[4] Li W, Gu C, Zhang H, Awang DV, Fitzloff JF, Fong HH, van Breemen RB. Use of high-performance liquid chromatography-tandem mass spectrometry to distinguish Panax ginseng C. A. Meyer (Asian ginseng) and Panax quinquefolius L. (North American ginseng). J Anal Chem 2000;72:5417–22.
[5] Su JH, Xu JH, Lu WY, Lin GQ. Enzymatic transformation of ginsenoside Rg3 to Rh2 using newly isolated Fusarium proliferatum ECU2042. J Mol Catal B Enzym 2006;38:113–8.
[6] Hu C, Song G, Zhang B, Liu Z, Chen R, Zhang H, Hu T. Intestinal metabolite compound K of panaxoside inhibits the growth of gastric carcinoma by aug-
menting apoptosis via Bid-mediated mitochondrial pathway. J Cell Mol Med 2012;16:96–106.
[7] Joh EH, Lee IA, Jung IH, Kim DH. Ginsenoside Rb1 and its metabolite com-
pound K inhibit IRAK-1 activation—the key step of inflammation. Biochem Pharmacol 2011;82:278–86.
[8] Han BH, Park MH, Han YN, Woo LK, Sankawa U, Yahara S, Tanaka O. Degra-
dation of ginseng saponins under mild acidic conditions. Planta Med 1982;44: 146–9.
[9] Kim WY, Kim JM, Han SB, Lee SK, Kim ND, Park MK, Kim CK, Park JH. Steaming of ginseng at high temperature enhances biological activity. J Nat Prod 2000;63:1702–4.
[10] Chang KH, Jo MN, Kim KT, Paik HD. Evaluation of glucosidases of Aspergillus niger strain comparing with other glucosidases in transformation of ginsenoside Rb1 to ginsenosides Rg3. J Ginseng Res 2014;38:47–51.
[11] Zhao X, Gao L, Wang J, Ji H, Gao J, Du X, Zhou Y, Tai G. A novel ginsenoside Rb1-hydrolyzing β-glucosidase from Cladosporium fulvum. Process Biochem 2009;44:612–8.
[12] Paek IB, Moon Y, Kim J, Ji HY, Kim SA, Sohn DH, Kim JB, Lee HS. Pharmaco-
kinetics of a ginseng saponin metabolite compound K in rats. Biopharm Drug Dispos 2006;27:39–45.
[13] Huo BY, Lu TJ, Chen CH, Wang SJ, Hwang IS. Biotransformation of ginsenoside Rd in the ginseng extraction residue by fermentation with lingzhi (Ganoderma lucidum). Food Chem 2013;141:4186–93.
[14] Yang XD, Yang YY, Ouyang DS, Yang GP. A review of biotransformation and pharmacology of ginsenoside compound K. Fitoterapia 2015;100:208–20.
[15] Leung KW, Wong AS. Pharmacology of ginsenosides: a literature review. Chin Med 2010;5:20 [Published online only].
[16] Wang HY, Hua HY, Li XY, Liu JH, Yu BY. In vitro biotransformation of red ginseng extract by human intestinal microflora: metabolites identification and metabolic profile elucidation using LC–Q-TOF/MS. J Pharm Biomed Anal 2014;98:296–306.
[17] Kim BG, Choi SY, Kim MR, Suh HJ, Park HJ. Changes of ginsenosides in Korean red ginseng (Panax ginseng) fermented by Lactobacillus plantarum M1. Process Biochem 2010;45:1319–24.
[18] Doh ES, Chang JP, Lee KH, Seong NS. Ginsenoside change and antioxidation activity of fermented ginseng. Korean J Med CropSci 2010;18:255–65.
[19] Kang BH, Lee KJ, Hur SS, Lee DS, Lee SH, Shin KS, Lee JM. Ginsenoside de-
rivatives and quality characteristics of fermented ginseng using lactic acid bacteria. Korean J Food Preserv 2013;20:573–82.
[20] Saqib AAN, Whitney PJ. Differential behaviour of the dinotroisalylic acid (DNS) reagent towards mono- and di-saccharide sugars. Biomass Bioenergy 2011;35:4748–50.
[21] Ávila M, Hidalgo M, Sánchez-Moreno C, Pelaez C, Requena T, de Pascual-
Teresas S. Bioconversion of anthocyanin glycosides by Bifidobacteria and Lactobacillus. Food Res Int 2009;42:1453–61.
[22] Ko JA, Park JY, Kwon HJ, Ryu YB, Jeong HJ, Park SJ, Kim CY, Oh HM, Park CS, Lim YH, et al. Purification and functional characterization of the first stibine gluco-
side–specific β-glucosidase isolated from Lactobacillus kimchi. Enzyme Microb Technol 2014;67:59–66.
[23] Pyo YH, Lee TC, Lee YC. Enrichment of bioactive isoflavones in soymilk fer-
mented with β–glucosidase–producing lactic acid bacteria. Food Res Int 2005;38:551–9.
[24] Van Q, Zhou W, Shi X, Zhou P, Ju D, Feng M. Biotransformation pathways of ginsenoside Rb1 to compound K by β–glucosidases in fungus Paecilomyces bainier sp. 229. Process Biochem 2010;45:1550–6.
[25] Quan LH, Piao JY, Min JW, Kim HB, Kim SR, Yang DU, Yang DC. Biotransfor-
mation of ginsenoside Rb1 to prosapogenins, gypenoside XVII, ginsenoside Rd, ginsenoside F2, and compound K by Leuconostoc mesenteroides DC102. J Ginseng Res 2011;35:344–51.
[26] Quan LH, Kim YJ, Li GH, Choi KT, Yang DC. Microbial transformation of gin-
senoside Rb1 to compound K by Lactobacillus paralimentum. World J Microbiol Biotechnol 2013;29:1001–7.
[27] Akao T, Kanoaka M, Kobashi K. Appearance of compound K, a major metab-
olite of ginsenoside Rb1 by intestinal bacteria, in rat plasma after oral administration—measurement of compound K by enzyme immunoassay. Biol Pharm Bull 1998;21:245–9.
[28] Choi HS, Kim SY, Park Y, Jung EE, Suh HJ. Enzymatic transformation of ginsenosides in Korean Red Ginseng (Panax ginseng Meyer) extract prepared by Spezyme and Optidex. J Ginseng Res 2014;38:264–9.
[29] Lee SM, Kim SC, Oh J, Kim JH, Na M. 20(R)-Ginsenoside RF: A new ginsenoside from red ginseng extract. Phytochem Lett 2013;6:620–4.
[30] Lee SM. The mechanism of acid-catalyzed conversion of ginsenoside RF and two new 25-hydroxylated ginsenosides. Phytochem Lett 2014;7:209–14.